Merck Healthcare has advised that Rebif® will be removed from the Pharmaceutical Benefits Scheme (PBS) from 1 December 2022. This affects the following products:
Rebif® Autoinjector
Interferon beta-1a 12 million units (44 mcg)/0.5 mL
ARTG 174479
Rebif® Pre-filled Syringe
Interferon beta-1a 12 million units (44 mcg)/0.5 mL
ARTG 133813
Rebif® Cartridge
Interferon beta-1a 36 million units (132 mcg)/1.5 mL
ARTG 165746
From 1 December 2022, PBS listings for the above products will be placed in a ‘Supply Only’ state until 31 March 2023 before being completely removed. During this period, these items can no longer be prescribed, but patients can continue to access outstanding repeats on prescriptions written prior to 1 December 2022.
Patients receiving treatment with Rebif® are encouraged to discuss their options with their treating specialist as soon as possible and before 31 March 2023, when their PBS prescription will no longer be valid.
Should you require further information regarding this matter, please contact Merck’s Medical Information Team on 1800 633 463 or via email at [email protected].
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates